ES2975662T3 - Biomarcadores y métodos de uso para la lesión pulmonar inducida por radiación - Google Patents

Biomarcadores y métodos de uso para la lesión pulmonar inducida por radiación Download PDF

Info

Publication number
ES2975662T3
ES2975662T3 ES19802268T ES19802268T ES2975662T3 ES 2975662 T3 ES2975662 T3 ES 2975662T3 ES 19802268 T ES19802268 T ES 19802268T ES 19802268 T ES19802268 T ES 19802268T ES 2975662 T3 ES2975662 T3 ES 2975662T3
Authority
ES
Spain
Prior art keywords
nampt
subject
rili
tissue
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19802268T
Other languages
English (en)
Spanish (es)
Inventor
Joe G N Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Original Assignee
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arizona filed Critical University of Arizona
Application granted granted Critical
Publication of ES2975662T3 publication Critical patent/ES2975662T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02012—Nicotinamide phosphoribosyltransferase (2.4.2.12), i.e. visfatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/40—Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES19802268T 2018-10-31 2019-10-31 Biomarcadores y métodos de uso para la lesión pulmonar inducida por radiación Active ES2975662T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862753802P 2018-10-31 2018-10-31
US201962896483P 2019-09-05 2019-09-05
PCT/IB2019/059379 WO2020089841A1 (en) 2018-10-31 2019-10-31 Biomarkers and methods of use for radiation-induced lung injury

Publications (1)

Publication Number Publication Date
ES2975662T3 true ES2975662T3 (es) 2024-07-11

Family

ID=68542675

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19802268T Active ES2975662T3 (es) 2018-10-31 2019-10-31 Biomarcadores y métodos de uso para la lesión pulmonar inducida por radiación

Country Status (8)

Country Link
US (2) US11733242B2 (enExample)
EP (2) EP3874273B1 (enExample)
JP (1) JP7534293B2 (enExample)
CN (1) CN113614535B (enExample)
AU (1) AU2019371161A1 (enExample)
CA (1) CA3117112A1 (enExample)
ES (1) ES2975662T3 (enExample)
WO (1) WO2020089841A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220403412A1 (en) * 2021-06-11 2022-12-22 Hui JING Baculovirus Of Recombinant Superoxide Dismutase Gene, Preparation And Application Thereof
CN114578058A (zh) * 2022-02-09 2022-06-03 中国人民解放军军事科学院军事医学研究院 一种放射损伤标志物bpifa2的应用及其相关试剂盒及试剂

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4415723A (en) 1982-03-19 1983-11-15 General Electric Company Randomly branched aromatic polycarbonate from triphenol
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
ATE88761T1 (de) 1986-01-10 1993-05-15 Amoco Corp Kompetitiver homogener test.
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
ATE92538T1 (de) 1988-01-21 1993-08-15 Genentech Inc Verstaerkung und nachweis von nukleinsaeuresequenzen.
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5932413A (en) 1988-04-01 1999-08-03 Celebuski; Joseph Eugene DNA probe assay using neutrally charged probe strands
US5187260A (en) 1988-09-06 1993-02-16 Sharifa Karali Process for the preparation of a high purity protamine-DNA complex and process for use of same
US5856092A (en) 1989-02-13 1999-01-05 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
US5075212A (en) 1989-03-27 1991-12-24 University Of Patents, Inc. Methods of detecting picornaviruses in biological fluids and tissues
US5849481A (en) 1990-07-27 1998-12-15 Chiron Corporation Nucleic acid hybridization assays employing large comb-type branched polynucleotides
US5645987A (en) 1990-09-21 1997-07-08 Amgen Inc. Enzymatic synthesis of oligonucleotides
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5849486A (en) 1993-11-01 1998-12-15 Nanogen, Inc. Methods for hybridization analysis utilizing electrically controlled hybridization
US5846708A (en) 1991-11-19 1998-12-08 Massachusetts Institiute Of Technology Optical and electrical methods and apparatus for molecule detection
FR2685346B1 (fr) 1991-12-18 1994-02-11 Cis Bio International Procede de preparation d'arn double-brin, et ses applications.
JP3633932B2 (ja) 1992-04-01 2005-03-30 ザ ジョーンズ ホプキンズ ユニバーシティー スクール オブ メディシン 糞便試料から単離した哺乳類の核酸を検出する方法、およびその検出用試薬
US5843640A (en) 1992-06-19 1998-12-01 Northwestern University Method of simultaneously detecting amplified nucleic acid sequences and cellular antigens in cells
US5861244A (en) 1992-10-29 1999-01-19 Profile Diagnostic Sciences, Inc. Genetic sequence assay using DNA triple strand formation
US5658751A (en) 1993-04-13 1997-08-19 Molecular Probes, Inc. Substituted unsymmetrical cyanine dyes with selected permeability
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
GB9311386D0 (en) 1993-06-02 1993-07-21 Pna Diagnostics As Nucleic acid analogue assay procedures
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
GB2284208A (en) 1993-11-25 1995-05-31 Pna Diagnostics As Nucleic acid analogues with a chelating functionality for metal ions
DE69432919T2 (de) 1993-12-28 2004-05-27 Tanabe Seiyaku Co., Ltd. Verfahren für den Nachweis spezifischer Polynukleotiden
US5599668A (en) 1994-09-22 1997-02-04 Abbott Laboratories Light scattering optical waveguide method for detecting specific binding events
DE69535240T2 (de) 1994-10-28 2007-06-06 Gen-Probe Inc., San Diego Zusammensetzungen und Verfahren für die gleichzeitige Detektion und Quantifizierung von einer Mehrheit spezifischer Nuklein Säure Sequenzen
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5929227A (en) 1995-07-12 1999-07-27 The Regents Of The University Of California Dimeric fluorescent energy transfer dyes comprising asymmetric cyanine azole-indolenine chromophores
US5916779A (en) 1995-09-21 1999-06-29 Becton, Dickinson And Company Strand displacement amplification of RNA targets
US5866331A (en) 1995-10-20 1999-02-02 University Of Massachusetts Single molecule detection by in situ hybridization
US5851772A (en) 1996-01-29 1998-12-22 University Of Chicago Microchip method for the enrichment of specific DNA sequences
US5912124A (en) 1996-06-14 1999-06-15 Sarnoff Corporation Padlock probe detection
US5853990A (en) 1996-07-26 1998-12-29 Edward E. Winger Real time homogeneous nucleotide assay
US6413544B1 (en) 1996-08-19 2002-07-02 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5853992A (en) 1996-10-04 1998-12-29 The Regents Of The University Of California Cyanine dyes with high-absorbance cross section as donor chromophores in energy transfer labels
US5853993A (en) 1996-10-21 1998-12-29 Hewlett-Packard Company Signal enhancement method and kit
US5900481A (en) 1996-11-06 1999-05-04 Sequenom, Inc. Bead linkers for immobilizing nucleic acids to solid supports
US5905024A (en) 1996-12-17 1999-05-18 University Of Chicago Method for performing site-specific affinity fractionation for use in DNA sequencing
US5846729A (en) 1997-02-27 1998-12-08 Lorne Park Research, Inc. Assaying nucleotides in solution using a fluorescent intensity quenching effect
US5846726A (en) 1997-05-13 1998-12-08 Becton, Dickinson And Company Detection of nucleic acids by fluorescence quenching
US5928869A (en) 1997-05-30 1999-07-27 Becton, Dickinson And Company Detection of nucleic acids by fluorescence quenching
US5919626A (en) 1997-06-06 1999-07-06 Orchid Bio Computer, Inc. Attachment of unmodified nucleic acids to silanized solid phase surfaces
US5935791A (en) 1997-09-23 1999-08-10 Becton, Dickinson And Company Detection of nucleic acids by fluorescence quenching
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
ES2220522T3 (es) 1999-08-18 2004-12-16 Ramot At Tel-Aviv University Ltd. Peptidos oralmente activos que evitan el daño y la muerte celular.
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
WO2002100325A2 (en) 2000-10-13 2002-12-19 Ligocyte Pharmaceuticals, Inc. Polyvalent nanoparticles
JP2005511761A (ja) 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ ナノ粒子送達ビヒクル
US20050143336A1 (en) 2003-12-30 2005-06-30 Board Of Regents, The University Of Texas System Methods and compositions for improved non-viral gene therapy
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
WO2011109650A1 (en) 2010-03-03 2011-09-09 The Board Of Trustees Of The University Of Illinois Method of treating acute lung injury using sphingosine 1 phosphate analoges or sphingosine 1 phosphate receptor agonists
CN103961691A (zh) * 2013-02-03 2014-08-06 复旦大学 尼克酰胺磷酸核糖转移酶在制备神经保护药物中的用途
ITTO20130356A1 (it) * 2013-05-03 2014-11-04 Uni Degli Studi Del Piemonte Orientale Ame Inibitori di nicotinamide fosforibosil transferasi, relative composizioni, prodotti ed usi
JP6793451B2 (ja) 2014-11-14 2020-12-02 キヤノンメディカルシステムズ株式会社 被検細胞の細胞特性を評価するための遺伝子マーカー、方法、レポーターベクター、プライマーセットおよびアッセイキット、並びに細胞特性評価装置
US20190023809A1 (en) 2015-09-03 2019-01-24 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
WO2018191747A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating pulmonary arterial hypertension
CN110945128B (zh) 2017-04-14 2023-11-03 代表亚利桑那大学的亚利桑那董事会 用于治疗肺纤维化的组合物和方法
CA3147020A1 (en) 2019-08-07 2021-02-11 Joe G.N. Garcia Anti-nampt antibodies and uses thereof
EP4010486A4 (en) 2019-08-07 2023-11-01 Arizona Board of Regents on behalf of the University of Arizona MONONUCLEOTIDE POLYMORPHISMS AND THEIR USES
CA3188685A1 (en) 2020-08-07 2022-02-10 Joe G.N. Garcia Single nucleotide polymorphisms and treatment of inflammatory conditions

Also Published As

Publication number Publication date
EP3874273B1 (en) 2024-03-27
EP3874273A1 (en) 2021-09-08
JP2022509018A (ja) 2022-01-20
AU2019371161A1 (en) 2021-06-17
JP7534293B2 (ja) 2024-08-14
EP4439066A2 (en) 2024-10-02
CN113614535B (zh) 2024-08-16
US11733242B2 (en) 2023-08-22
WO2020089841A1 (en) 2020-05-07
CN113614535A (zh) 2021-11-05
US20240085422A1 (en) 2024-03-14
EP3874273C0 (en) 2024-03-27
CA3117112A1 (en) 2020-05-07
US20200132689A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
ES2607851T3 (es) Objetivos novedosos para la regulación de la angiogénesis
ES2995194T3 (en) Method for the prognosis and treatment of cancer metastasis
ES2434945T3 (es) Identificación de antígenos asociados a tumores para el diagnóstico y la terapia
ES2744244T3 (es) Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF
ES2727904T3 (es) Método para el pronóstico y tratamiento de cáncer metastatizante del hueso que se origina a partir de cáncer de mama
ES2293114T3 (es) Medios y metodos para diagnosticar y tratar trastornos afectivos.
ES2839456T3 (es) Proteína 2 que contiene el dominio del esperma móvil y del cáncer
AU3458401A (en) Compositions and methods for treatment of cancer
US20170114124A1 (en) SLIT-ROBO-Myo9-RHOA PATHWAY AND CANCER
US20240085422A1 (en) Biomarkers and methods of use for radiation-induced lung injury
JP5756014B2 (ja) がんの診断および治療のためのｖｈｚ
EP3088001B1 (en) Anti-lipolysis stimulated liporotein receptor antibodies for treatment of ovarian cancer
US20210087247A1 (en) Mps peptides and use thereof
Huang et al. RETRACTED ARTICLE: RAB43 Promotes Gastric Cancer Cell Proliferation and Metastasis via Regulating the PI3K/AKT Signaling Pathway
WO2011054644A1 (en) A low density lipoprotein-related protein 1 splice variant as cancer marker
JP2015518367A (ja) 腸透過性のｅｇｆｒおよびｐａｒ２の調節
ES2371479T3 (es) Uso de aimp2dx2 para el diagnóstico y tratamiento del cáncer.
US9822184B2 (en) DCLK1 short form specific binding agents
KR102270926B1 (ko) Banf1, plod3 또는 sf3b4의 억제제를 유효성분으로 포함하는 간암의 예방 및 치료용 조성물
WO2025003680A1 (en) Method for identifying specific cancer patient subgroups and novel cancer therapy for specific cancer patient subgroups
WO2024036192A2 (en) Compositions and methods for assessing the severity of and treating covid-19
WO2016187392A2 (en) Methods and compositions relating to anti-tmigd1/igpr-2
JPWO2005021739A1 (ja) Ｎｏｘ１ポリペプチドに対する抗体、Ｎｏｘ１遺伝子を利用したガン診断方法、及びガン増殖抑制物質のスクリーニング方法
AU2003287764A1 (en) A novel phosphoprotein